Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-12 04:31:30 EDT

Explore

PostsPeople
LatestRanked
Load more
@boehringerglobal.bsky.socialOct 1, 2026, 7:36 AM

#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social

These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels.

👉 go.boehringer.com/SBqTr

#LifeForward #EASD2026

@foodnourish.bsky.socialOct 1, 2026, 7:25 AM

📣 New Podcast! "Why Childhood Obesity Rates Are Skyrocketing" on @Spreaker #activity #behavior #childhood #diet #disparities #epidemic #exercise #fitness #food #health #healthier #lifestyle #medicine #nutrition #obesity #parenting #pediatrics #prevalence #prevention #wellness

@easoobesity.bsky.socialOct 1, 2026, 7:07 AM

The EU intends to reduce premature cardiovascular deaths by 25% by 2035 through its #SafeHearts plan. Address #obesity to reduce diabetes prevalence and CV risk

commission.europa.eu/news-and-med...

@thelancetendo.bsky.socialOct 1, 2026, 7:04 AM

New Editorial:
Safeguarding paediatric metabolic health www.thelancet.com/journals/lan...
#obesity
#FREE to read

#MedSky #EndoSky

@easdnews.bsky.socialOct 1, 2026, 7:01 AM

🔬Happening now at #EASD2026. Clinical trial presentations exploring new approaches to #T2D & #obesity:

1️⃣ 08:30 Orforglipron | 📍Budapest Hall
2️⃣ 09:30 SMARTEST |📍 Budapest Hall
3️⃣ 09:30 SYNCHRONIZE | 📍Dublin Hall
4️⃣ 09:30 RESET for REMISSION | 📍Vienna Hall

Explore now 👉 www.easd.org/annual-meeti...

@newsanalysis.comOct 1, 2026, 6:43 AM

Eli Lilly's experimental combo therapy of eloralintide and tirzepatide showed greater weight loss than tirzepatide alone in a mid-stage trial for obesity and Type 2 diabetes patients. The combination targets amylin, GLP-1, and GIP hormones. #obesity #News

@jmirlatestresearch.bsky.socialSep 30, 2026, 8:54 PM

New in JMIR mhealth: Noninvasive Interstitial Glucose Estimation Using #Wearables and Machine Learning in Healthy Individuals and Individuals With #Obesity: Observational Cohort Study

@rcatanho.bsky.socialSep 30, 2026, 4:06 PM

La mayoría de los candidatos a cirugía bariátrica metabólica cumplen criterios para obesidad clínica, y tienen una mayor carga de enfermedad, mayor riesgo quirúrgico y mayor riesgo CV estimado #obesity #metabolic #bariatric #surgery jamanetwork.com/journals/jam...

@midgardfinance.comSep 30, 2026, 3:00 PM

💉 #obesity #EASD2026

🇩🇰 Zealand's #petrelintide, partnered with 🇨🇭 Roche, Phase 2 ZUPREME-1 in The Lancet Diabetes & Endocrinology, week 42:

1 mg: -8.7%
5 mg: -10.7%
9 mg: -10.2%
Placebo: -1.7%

Nine times the dose adds 1.5 points. Vomiting 3%, below placebo's 6%.

$ZEAL $RO

Bar chart of average weight change at week 42 in the phase 2 ZUPREME-1 trial of petrelintide, Zealand Pharma's weekly amylin injection partnered with Roche, published in The Lancet Diabetes and Endocrinology on 29 September 2026. One grey bar for placebo and five blue bars for the weekly doses: placebo -1.7 per cent, 1 mg -8.7 per cent, 2.5 mg -9.2 per cent, 5 mg -10.7 per cent, 7 mg -10.5 per cent, 9 mg -10.2 per cent. The five dose bars are almost the same height: the lowest dose loses 8.7 per cent and the highest 10.2 per cent, and the deepest arm is 5 mg, not the top dose. Figures are for patients who stayed on treatment.
@phenomics.bsky.socialSep 30, 2026, 2:02 PM

❤️ Beyond body size: A Phenomics study examines longitudinal associations between metabolic heterogeneity of obesity and ECG phenotypes in an older population.

doi.org/10.1007/s436...

#Phenomics #Obesity

@midgardfinance.comSep 30, 2026, 12:30 PM

💉 #obesity #EASD2026

🇺🇸 Lilly's #retatrutide 12 mg, 80 weeks, two Phase 3 trials published this week:

Without diabetes (TRIUMPH-1, NEJM): -28.3%
With type 2 diabetes (TRIUMPH-2, Lancet): -20.8%

Same drug, same dose. Type 2 diabetes costs about a quarter of the weight loss.

$LLY

Line chart of average weight change over 80 weeks on retatrutide 12 mg in two phase 3 trials published on 29 September 2026. The line that falls further is TRIUMPH-1 (New England Journal of Medicine), adults with obesity and no diabetes; the shallower line is TRIUMPH-2 (The Lancet), adults with obesity and type 2 diabetes. Both lines fall steeply for the first 36 weeks and flatten after week 52. The lines show the published average of patients on treatment, ending at -27.6 and -21.3 per cent at week 80. The two dots to the right are each trial's estimate for patients who stayed on the drug: -28.3 per cent without diabetes and -20.8 per cent with type 2 diabetes, a gap of 7.5 points. These are separate trials with different participants, so the gap is not a randomised comparison, although the drug, dose, duration and method are the same.
@pharmaphorum.bsky.socialSep 30, 2026, 11:24 AM

#EliLilly's triple G agonist #retatrutide has achieved impressive #weightloss in patients with #type2diabetes and #obesity, boosting its credentials as the next big thing in #cardiometabolicdiseases.

pharmaphorum.com/news/lilly-f...

@metabologiajnl.bsky.socialSep 30, 2026, 6:35 AM

Metabologia wants your research papers on the #metabolic aspects of #diabetes, #obesity, #CVD and #renal and #hepatic disease #comorbidity #nutrition #exercise #psychosocial #healtheconomics #healthtechnology – submit now! metabologia.org #EASD2026

@thelancetendo.bsky.socialSep 30, 2026, 6:27 AM

Sten Madsbad & Jens J Holst comment on:
Petrelintide and the evolving role of amylin agonism in obesity thelancet.com/journals/lan...
#obesity
#EASD2026

#MedSky #EndoSky

@thelancetendo.bsky.socialSep 30, 2026, 6:27 AM

New—Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial thelancet.com/journals/lan...
#obesity
#EASD2026

#MedSky #EndoSky

(A) Estimated mean change in bodyweight by treatment week (efficacy estimand). (B) Least squares mean change in bodyweight from baseline to week 42 (efficacy estimand). (C) Observed mean change in bodyweight by treatment week (treatment policy estimand). (D) Least squares mean change in bodyweight (%) from baseline to week 42 (treatment policy estimand). *p<0·0001 for difference versus placebo. †Treatment policy estimates at week 42.
@obesityadvisor.bsky.socialSep 29, 2026, 8:31 PM

September roundup: Top clinical updates on #obesityManagement.

🩺 Experts Discuss ACP Guidelines for Management of Overweight and #Obesity in Adults
https://bit.ly/4zGWIGZ
With @acpimphysicians.bsky.social, Thomas Cross, MD and Doug Owens, MD of @stanforduniversity.bsky.social

#KOLCorner

(1/5)

@rcatanho.bsky.socialSep 29, 2026, 3:49 PM

Firmas neurales del riesgo de obesidad ya son detectables en los preescolares, destacando la ventana crítica de desarrollo para la intervención preventiva #brain #structure #child #obesity newsletter.smartbrief.com/sharedSummar...

@isev.orgSep 29, 2026, 2:30 PM

🆕New in #JEV🆕 Extracellular Vesicle-Encapsulated Small RNAs From Clostridium Butyricum Modulate Host Intestinal Lipid Metabolism #extracellularvesicles #gutmicrobiota #lipidmetabolism #obesity isevjournals.onlinelibrary.wiley.com/doi/epdf/10....

@pharmalot.bsky.socialSep 29, 2026, 1:54 PM

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more news.. statnews.com/pharmalot/20... #pharma #obesity #antibiotic #jobs #China #weight #Novo #Roche #Merck #AstraZeneca #Baltimore #Bausch